AbCellera Biologics (ABCL) Research & Development (2020 - 2026)
AbCellera Biologics' (ABCL) quarterly Research & Development came in at $46.7 million in Q1 2026, up 9.8% YoY from $42.5 million in Q1 2025, and down 6.85% on a QoQ basis from $50.1 million in Q4 2025.
AbCellera Biologics (ABCL) Research & Development (2020 - 2026) Analysis & Trends
AbCellera Biologics (ABCL) has 7 years of Research & Development data on file, last reported at $46.7 million in Q1 2026.
- Quarterly Research & Development rose 9.8% year-over-year to $46.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $138.9 million (down 32.71% YoY) and the FY2025 annual result came in at $186.8 million, up 11.7% from the prior year.
- Research & Development slipped to $46.7 million in Q1 2026, from $50.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $157.6 million in Q4 2024 to a low of $2.9 million in Q3 2025.
- A 5-year average of $39.3 million and a median of $37.9 million in 2023 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development soared 1960.62% — and 2024, when it slumped 91.73%.
- Tracing ABCL's Research & Development over 5 years: stood at $28.2 million in 2022, then surged by 72.14% to $48.6 million in 2023, then jumped by 224.18% to $157.6 million in 2024, then sank by 68.22% to $50.1 million in 2025, then slipped by 6.85% to $46.7 million in 2026.
- The last three Research & Development figures came in at $46.7 million (Q1 2026), $50.1 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.37 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 394.92 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 612.28 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1,146.05 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 97.90 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 413.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 210.03 Mn |
| 10 | AbCellera Biologics | 3.49 Bn | 3.49 Bn | - | 45.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45.99 Mn |
| Mar 31, 2026 | 46.66 Mn |
| Dec 31, 2025 | 50.09 Mn |
| Sep 30, 2025 | 2.91 Mn |
| Jun 30, 2025 | 39.21 Mn |
| Mar 31, 2025 | 42.50 Mn |
| Dec 31, 2024 | 157.62 Mn |
| Sep 30, 2024 | 3.14 Mn |
| Jun 30, 2024 | 3.14 Mn |
| Mar 31, 2024 | 39.29 Mn |
| Dec 31, 2023 | 48.62 Mn |
| Sep 30, 2023 | 37.92 Mn |
| Jun 30, 2023 | 36.47 Mn |
| Mar 31, 2023 | 52.65 Mn |
| Dec 31, 2022 | 28.25 Mn |
| Sep 30, 2022 | 26.58 Mn |
| Jun 30, 2022 | 26.69 Mn |
| Mar 31, 2022 | 26.37 Mn |
| Dec 31, 2021 | 56.98 Mn |
| Sep 30, 2021 | 17.45 Mn |